Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an increase in revenue. The company also raised its full-year earnings guidance.
Net revenues increased to $15.8 billion in the September quarter from $14.5 billion in the corresponding period of fiscal 2024.
Net earnings, on an adjusted basis, declined to $1.86 per share in the third quarter from $3.0 per share in the year-ago quarter. Net income attributable to the company, on a reported basis, was $186 million or $0.10 per share in Q3, compared to $1.56 billion or $0.88 per share last year.
The management raised its full-year 2025 adjusted earnings guidance range from $10.38-0.58 per share to $10.61-$10.65 per share. The revised guidance includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
BLK Q4 Preview: BlackRock appears poised for another earnings beat
BlackRock, Inc. (NYSE: BLK), the largest asset management company, is expected to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s
A look at Best Buy’s (BBY) progress on its growth strategy
Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and
Citigroup set to report Q4 2025 earnings. Here’s what to expect
Citigroup Inc. (NYSE: C) has undergone a sweeping transformation in recent years, emerging as a more streamlined and profitable financial institution. The bank's performance in recent quarters has underscored the
